BIOPTIC: Anticipatory AI for Pharmaceutical Intelligence

BIOPTIC is an AI platform designed to empower pharmaceutical companies with anticipatory intelligence by analyzing global filings, clinical trials, and patents across 100+ languages. Built by a team of AI and biopharma experts, BIOPTIC uses AI agents trained on curated, domain-specific data to deliver accurate insights on assets, risks, and opportunities before market shifts. The platform accelerates discovery, due diligence, and commercialization processes, helping biotech leaders make data-driven decisions faster. With a focus on scientific rigor and innovation, BIOPTIC combines deep domain knowledge with advanced AI to transform how pharmaceutical intelligence is gathered and applied.

Key Features:

• Global Filings & Trials Analysis: Comprehensive monitoring of clinical trials, regulatory submissions, and patents across 100+ languages.
• Anticipatory AI Intelligence: Proactive insights on market shifts, asset opportunities, and potential risks.
• Pharma-Specific AI Agents: Trained on curated biopharma data to prevent hallucinations and ensure accuracy.
• Accelerated Discovery & Due Diligence: Streamlines processes for identifying promising drug candidates and evaluating competitive landscapes.
• AI Drug Discovery Tools: Includes breakthrough systems for molecule screening, such as an AI system targeting LRRK2.
• Scientific Benchmarking: Released PLUMBER, a benchmark for AI-driven binding prediction.
• Target-Agnostic Search Engine: White paper on a potency-based small molecule search engine.
• Peer-Reviewed Research: Publications in journals like the Journal of Chemical Information and Modeling (JCIM).

Pricing: BIOPTIC offers a free trial and early access invites, with pricing available upon request. The platform is tailored for enterprise clients, with custom plans based on needs and scale.

Conclusion: BIOPTIC stands at the intersection of AI and biopharma, offering a powerful, accurate, and forward-looking intelligence platform that helps pharmaceutical and biotech companies stay ahead in a rapidly evolving industry.